Selected Refereed Journal Articles

  • Choueiri, TK, Michaelson, MD, Posadas, EM, Sonpavde, GP, McDermott, DF, Nixon, AB, Liu, Y, Yuan, Z, Seon, BK, Walsh, M, Jivani, MA, Adams, BJ, and Theuer, CP. (2019) An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.” The Oncologist 24, 2: 202-210. https://www.ncbi.nlm.nih.gov/pubmed/30190302 

 

  • Liu Y, Starr MD, Brady JC, Rushing C, Pang H, Adams B, Alvarez D, Theuer CP, Hurwitz HI, Nixon AB (2018) Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody TRC105. Mol Cancer Ther. Oct;17(10): 2248-2256  http://mct.aacrjournals.org/content/17/10/2248

 

 

  • Seligmann JF, Hatch AJ, Richman SD, Elliott F, Jacobs B, Brown S, Hurwitz H, Barrett JH, Quirke P, Nixon AB, Seymour MT. (2017) Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. JAMA Oncol. 2018 Apr 1;4(4):564-568.  https://jamanetwork.com/journals/jamaoncology/fullarticle/2659372

 

  • Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, Innocenti F, Venook AP, Hurwitz HI, Nixon AB (2016)Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Med. Sep;5(9):2249-2260   https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.806

 

  • Kim, H.L., Halabi, S., Ping, L., Mayhew, G., Simko, J., Nixon, A.B., Small, E.J., Rini B.I., Morris, M.I., Taplin, M.E., George, D.G. (2015) A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). EBioMedicine Nov; 2(11):1814-1820.  https://www.sciencedirect.com/science/article/pii/S2352396415301328?via%3Dihub

 

 

  • Jia J, Dellinger A, Bulusu A, Weiss E, Rushing C, Li H, Howard L, Kaplan N, Pang H, Hurwitz H, Nixon AB. (2015) Direct Evidence of Target Inhibition with anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. Clin Cancer Res. Aug;21(15):3442-3452.   http://clincancerres.aacrjournals.org/content/21/15/3442.long

 

  • Liu Y, Starr MD, Brady JC, Rushing C, Bulusu A, Pang H, Honeycutt W, Amara A, Altomare I, Uronis HE, Hurwitz HI, Nixon AB. (2015) Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus. Mol Cancer Ther. Apr;14(4):1048-56.  http://mct.aacrjournals.org/content/14/4/1048.long

 

  • Cushman S, Jiang C, Hatch A, Shterev I, Sibley A, Niedzwiecki D, Venook AP, Owzar K, Hurwitz HI, Nixon AB. (2015) Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance). Clin Cancer Res. Mar 1;21(5):1078-1086.   http://clincancerres.aacrjournals.org/content/21/5/1078.long

 

 

 

 

 

  • Liu Y, Starr MD, Bulusu A, Pang H, Wong NS, Honeycutt W, Amara A, Hurwitz HI,Nixon AB. (2013) Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med. 2(2):234-242.  https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.71

 

  • Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, Hector-Greene M, Sun L, Tewari A, George A, Starr M, Nixon A, Augustine C, Beasley G, Tyler DS, Osada T, Morse MA, Ling L, Lyerly HK, Blobe GC. (2013) Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. Clin. Invest. 123(9):3925-40.  https://www.jci.org/articles/view/65745

 

  • Jia J, Starodub A, Cushman I, Liu Y, Marshall DJ, Hurwitz HI, Nixon AB. (2013)Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. Anticancer Drugs. 24(3):237-250.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828660/

 

 

  • Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H.I., Dev, I., Nixon, A.B., Lyerly, H.K., Clay, T., Morse, M.A. (2008) The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57:1152-24.  https://link.springer.com/article/10.1007%2Fs00262-007-0441-x